| Autor: |
Dzau V; US National Academy of Medicine, Washington, DC, USA., Swaminathan S; M S Swaminathan Research Foundation, Chennai, India., Baker C; International Pandemic Preparedness Secretariat, London NW1 2BE, UK. Electronic address: c.baker@ippsecretariat.org., Bright RA; Foundation for Innovative New Diagnostics, Geneva, Switzerland., Castillo J; Univercells, Nivelles, Belgium., Chuan TC; Singapore Ministry of Health, Singapore., Draghia-Akli R; Johnson & Johnson, New Brunswick, NJ, USA., Eardley-Patel R; Coalition of Epidemic Preparedness Innovations, London, UK., Gao GF; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China., Ishii K; Institute of Medical Science, University of Tokyo, Tokyo, Japan., Tebeje YK; Africa Centres for Disease Control and Prevention, African Union Commission, Addis Ababa, Ethiopia., Lambe T; Medical Sciences Divison, University of Oxford, Oxford, UK., Machingaidze S; Africa Centres for Disease Control and Prevention, African Union Commission, Addis Ababa, Ethiopia., Røttingen JA; Norwegian Foreign Ministry, Oslo, Norway., Shaligram U; Serum Institute of India, Pune, India., Simão M; Instituto Todos Pela Saúde, São Paulo, Brazil., Swarup R; Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India., Toussaint JF; Sanofi Vaccines, Gentilly, France., Wairagkar NS; Africa Centres for Disease Control and Prevention, African Union Commission, Addis Ababa, Ethiopia. |
| Abstrakt: |
Competing Interests: All authors, except CB, are members of the Science and Technology Expert Group for the 100 Days Mission. CB is the Deputy Head of the International Pandemic Preparedness Secretariat, which is hosted by Wellcome, and is a former employee of WHO. VD is the President of the US National Academy of Medicine. SS is the former Chief Scientist at WHO. RAB is the former Director of the US Biomedical Advanced Research and Development Authority (BARDA), is on the Scientific Advisory Board for Qiagen, is on the Board of Directors for Foundation for Innovative New Diagnostics, and holds stock in Cue Health. JC is the Chief Technology Officer of Univercells and the Chief Executive Officer of Quantoom Biosciences. TCC is the Chief Health Scientist at the Singapore Ministry of Health and is the Executive Director of the Office for Healthcare Transformation of the Singapore Ministry of Health. RD-A is the Global Head at Johnson & Johnson Global Public Health Research and Development, which receives grants and contracts from BARDA, the US National Institutes of Health (NIH), the EU (including the Innovative Health Initiative), the Bill & Melinda Gates Foundation, Flanders Agency Innovation and Entrepreneurship, the European and Developing Countries Clinical Trials Partnership, and the Singapore Agency for Science, Technology and Research; is Co-Chair of the Therapeutics Clinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines at NIH; is a board member of the INTREPID Alliance; is a member of the American Society of Gene Therapy; and holds stock and stock options with Merck Sharp & Dohme and Johnson & Johnson. RE-P is the acting Chief of Staff for the Coalition of Epidemic Preparedness Innovations (CEPI) Manufacturing and Supply Chain division. GFG is the Dean of the Savaid Medical School (University of Chinese Academy of Sciences, Beijing, China). KI is the Director of the International Vaccine Design Center (Institute of Medical Science, University of Tokyo, Tokyo, Japan) and is a member of Scientific Advisory Committees for CEPI and the Global Health Innovative Technology Fund. YKT is the Head of the Division of Laboratory Systems and Networks at Africa Centres for Disease Control and Prevention (Africa CDC). TL received support through a grant from the University of Oxford (Oxford, UK) to support the running of the Vaccine Taskforce via the UK National Institute for Health and Care Research trial and the AstraZeneca partnership for development of COVID-19 vaccines, was a consultant to Vaccitech, and is an inventor on a patent application for a vaccine against SARS CoV-2. SM is Chief Science Officer for Africa CDC. J-AR is the Ambassador for Global Health at the Norwegian Ministry of Foreign Affairs; is a Gavi, the Vaccine Alliance board member representing the Nordic+ constituency; and is the former technical-level Co-Chair of the Access to COVID-19 Tools Accelerator Facilitation Council. US is the Executive Director of the Serum Institute of India. MS is the former WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals. RS is the former Secretary of the Department of Biotechnology at the Indian Ministry of Science and Technology. J-FT is the Head of Research and Development at Sanofi Vaccines; owns shares from Sanofi; and received shares from GlaxoSmithKline until January, 2021, as a former employee. NSW is the Founder and Chief Executive Officer of Vaccines for All and is a consultant to Africa CDC for the Partnership for Africa Vaccine Manufacturing initiative at CEPI India. |
